The company is working with the University of Florida Health Cancer Center to validate its RadTox QuantiDNA test as a monitor of cfDNA in patient plasma.
The company has received grant funding for diagnostic development projects, and is also seeking its first pharma service customers to provide nearer-term revenue.
The genetic screening firm validated the modifications with a Phase I SBIR grant from NIH and is seeking a Phase II grant to target critical protein domains.
The SBIR grant could be worth as much as $2.3 million and will help PapGene develop and commercialize its proprietary ovarian and endometrial cancer detection test.
